Philadelphia, PA, March 2022 – The American Association for Cancer Research (AACR) is currently accepting nominations for the AACR Daniel D. Von Hoff Award, named after Stromatis Pharma’s founder Dr. Daniel D. Von Hoff. Stromatis Pharma is a private biotech company located in Prince William County’s Innovation Park, VA. Stromatis is committed to developing therapeutics for patients with difficult-to-treat cancers using their innovative proprietary antibody-discovery platform. They create superior and highly specific immunotherapies (including ADCs). They are striving to discover additional targets for unmet cancer needs.
This award serves to honor Dr. Von Hoff’s sustained and extraordinary accomplishments as a dedicated and inspirational educator and his innovative thinking about how to accelerate advances in cancer science and medicine. Dr. Von Hoff’s professional guidance of young clinical fellows and junior clinical faculty has contributed to their professional background and training and their ability to apply learned principles to improve the care of countless cancer patients worldwide.
This award is for Outstanding Contributions to Education and Training in Cancer Research. The AACR committee intends to honor an individual in any subfield or sector of cancer research and cancer-related sciences who has significantly contributed to the education and training of cancer researchers. This award can also be given to other professionals at all career levels, especially to early-career early-stage investigators.
The eligibility of this award extends to individuals affiliated with any institution involved in cancer research, cancer medicine, or cancer-related sciences anywhere in the world may be nominated. Such institutions include those in academia, industry, or government. Nominations are due September 15, 2022. For more information, go to https://www.aacr.org/awards/aacr-daniel-von-hoff-award-aacr-scientific-awards.
Stromatis Pharma Contact:
Guy Yachin, MBA
(301) 633-0393
guy.yachin@gmail.com
Source: Stromatis Pharma, Inc.